| Filed On | Filing |
|---|---|
| 27 Oct 2026 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 3... |
| 17 Sep 2026 |
8-K: Other Events
pre-funded warrants to purchase 1,043,484 Shares of Common Stock |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking s... |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 20... |
| 22 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 21, 2026, Beta Bionics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Company’s definitive proxy statement for the Annual Meeting was filed with the U.S. Securities and Exchange Comm... |
| 21 May 2026 |
8-K: Regulation FD Disclosure; Other Events
IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully commercialize Mint by the end ... |
| 21 Apr 2026 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, ... |
| 17 Feb 2026 |
8-K: Results of Operations and Financial Condition
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026 |
| 30 Jan 2026 |
8-K: Other Events
On January 29, 2026, Beta Bionics, Inc. (the “Company”) received a warning letter (the “Warning Letter”) from the U.S. Food and Drug Administration (the “FDA”) following inspection of the Company’s facility in Irvine, California that occ... |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results an... |
| 28 Oct 2025 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 3... |
| 29 Jul 2025 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 20... |
| 23 Jun 2025 |
8-K: Regulation FD Disclosure
Disclaimer 2 This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward - loo... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 20... |
| 27 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 25 Mar 2025 |
8-K: Results of Operations and Financial Condition
Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025 |
| 31 Jan 2025 |
8-K: Unregistered Sales of Equity Securities; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
Beta Bionics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: |
Loading...